XSTO
LARK
Market cap5mUSD
Jun 25, Last price
2.47SEK
Name
Combigene AB
Chart & Performance
P/E
—
P/S
150.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
46.15%
Rev. gr., 5y
-53.49%
Revenues
326k
-94.12%
Net income
-45m
L+25.83%
CFO
-30m
L-1.99%
Dividend
Jun 13, 20250.2 SEK/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Lidingö, Sweden, CombiGene AB (publ) was established in 1999 and specializes in pioneering gene therapy solutions for severe, life-altering medical conditions. The company is currently advancing two primary gene therapy candidates in its pipeline. CG01, a treatment targeting epilepsy, is undergoing preclinical trials that include detailed biodistribution and toxicology assessments. Its second candidate, CGT2, is under development for addressing lipodystrophy. CombiGene also maintains strategic alliances, including a licensing and collaborative agreement with Lipigon Pharmaceuticals AB to create a gene therapy for partial lipodystrophy, and a partnership with Spark Therapeutics for the advancement of adeno-associated virus (AAV) based gene therapies.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||